Muir-Torre syndrome is a clinical variant of Lynch syndrome defined by the synchronous or metachronous occurrence of at least one sebaceous neoplasm and at least one Lynch syndrome-related internal cancer. Although screening guidelines for patients with colorectal carcinomas have been established, screening guidelines for cutaneous Muir-Torre associated neoplasms are not currently available. As such, we reviewed the current evidence for the use of MLH1, MSH2, MSH6 and PMS2 immunohistochemistry when cutaneous Muir-Torre associated neoplasms are encountered. We identified weak to moderate support overall for the global use of these assays, with some evidence suggesting a tailored approach using clinical parameters as an adjunct. We also assessed the current utilization patterns of attendees of the American Society of Dermatopathology Annual Meeting (Chicago, 2016). We found that 91% of respondents utilize mismatch repair immunohistochemistry, with the majority utilizing these tests only when requested by the submitting clinician. 
Muir-Torre syndrome is a clinical variant of Lynch syndrome defined by the synchronous or metachronous occurrence of at least one sebaceous neoplasm and at least one Lynch syndrome-related internal cancer. Although screening guidelines for patients with colorectal carcinomas have been established, screening guidelines for cutaneous Muir-Torre associated neoplasms are not currently available. As such, we reviewed the current evidence for the use of MLH1, MSH2, MSH6 and PMS2 immunohistochemistry when cutaneous Muir-Torre associated neoplasms are encountered. We identified weak to moderate support overall for the global use of these assays, with some evidence suggesting a tailored approach using clinical parameters as an adjunct. We also assessed the current utilization patterns of attendees of the American Society of Dermatopathology Annual Meeting (Chicago, 2016). We found that 91% of respondents utilize mismatch repair immunohistochemistry, with the majority utilizing these tests only when requested by the submitting clinician. In both syndromes, mutations in the genes encoding for MSH2
and MLH1 account for the majority of the cases and isolated mutations in MSH6 and PMS2 account for a small minority. While the frequency of MLH1 germline mutation is slightly higher than that for MSH2 in colorectal carcinoma, MSH2 gene mutation represents the dominant mutation in cutaneous sebaceous neoplasms accounting for 68% to 93% of the cases. A literature review to identify the current scientific evidence behind the use of MMR IHC when MTS-associated cutaneous neoplasms are encountered was performed. Next, the scientific evidence was enumerated, evaluated and summarized. Finally, we utilized an audience response system during short course I "Best Practices" at the 51st Annual Meeting of the ASDP in Chicago, Illinois, to assess the current utilization patterns of attendees.
| MATERIALS AND METHODS

| Literature review
In order to identify and evaluate MMR IHC in MTS-associated cuta- 
| Survey of current utilization
During the 51st Annual Meeting of the ASDP in Chicago, Illinois, an audience response system surveyed attendees of short course I "Best
Practices" regarding their current utilization of HPV ISH and IHC and MMR IHC. The audience was polled prior to the presentation of the literature overview using a web-based platform that allowed anyone in the audience with a smartphone, tablet or any other internetconnected device to participate in the poll. Most studies have been performed on sebaceous neoplasms and only a few keratoacanthomas were evaluated.
Among the larger series, 25% to 66% of the sebaceous neoplasms demonstrated abnormal MMR IHC. 4, 5, 7, 11, 19 In one study, it was as high as 80% but the participants of the study were high-risk patients identified by geneticists. 5 These studies also confirm that the loss of MSH2 expression is more frequent than MLH1 in sebaceous neoplasms and that the loss is more commonly observed in extrafacial sebaceous neoplasms. 7, 11, 19 Sensitivity of MMR IHC on sebaceous neoplasms in detecting germline MMR gene mutation reach as high as 81% with a positive predictive value reaching 44%. 4, 5 In the few studies where germline mutation analyzes were included, 37% to 50% of the cases with abnormal MMR IHC were confirmed by a germline mutation test. 4, 5, 10 These results indicate a high false positivity rate when screening sebaceous neoplasms for MTS presumably because of somatic nonheritable molecular events. 4 When patients with known MTS have their sebaceous neoplasms tested, however, a high rate of concordant MMR IHC abnormality is observed, reflective of their germline mutation. 3, 27 In a cohort of patients with or without visceral malignancy, a higher rate of MMR deficiency was observed in sebaceous neoplasms in those with a visceral malignancy. 27 A higher likelihood of MMR IHC abnormality is observed in extrafacial sebaceous neoplasms.
4,14
Moreover, multiple sebaceous neoplasms confer higher specificity for MTS. 4 In a retrospective population-based analysis, 5.8% (7/120) of individuals who presented with MTS-associated skin neoplasms had visceral malignancy. 21 In addition, 22.3% (19/85) of patients with a sebaceous neoplasm had a visceral malignancy in a retrospective analysis performed by two large academic institutions. 11 The discrepancy in frequency may be explained by the different settings in which the studies were conducted. One study was population-based vs the second study which was conducted at referral centers where high-risk patients are seen.
Two studies that evaluated periorbital and conjunctival sebaceous neoplasms were reviewed. Although the sample sizes are small, lower prevalence of MMR protein defect was observed, particularly in sebaceous carcinomas. 13, 22 Only one study directly compared a 2-antibody panel with a 4-antibody panel in detecting abnormal expression of MMR protein. (Table 2) . 12 We used an audience response system at the 53rd Annual Abbreviations: CS, case series; KA, keratoacanthoma; NA, not applicable; NE, not examined; NS, not specified; PC, prospective cohort; pts, patients; RC, retrospective cohort; SN, sebaceous neoplasm.
a
Only performed on cases that demonstrated loss of MSH6.
overall body of evidence suffers issues stemming from retrospective nature of most studies, small sample size, heterogeneity in study methodology and objectives, lack of confirmatory germline mutation when needed, and selected patients from major referral centers that may not reflect the population at large. As the work of the AUC Task
Force continues, we will use an expert panel and the RAND/UCLA Appropriateness Method to determine whether the use of these tests is "appropriate," "inappropriate" or "uncertain" in each clinical setting.
